By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel agrees that the recent Medicare changes, particularly the tightening of Medicare Advantage (MA) supplemental benefits and drug price negotiations, pose significant risks to MA plans' profitability and growth. The changes could lead to a reduction in enrollment growth, margin compression for Big Pharma, and potential increases in premiums or network narrowing by MA plans to offset losses.
Risk: The collapse of the star-rating/rebate growth engine for MA plans, potentially leading to aggressive network narrowing or premium increases to offset margin loss.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
It's important you know the truth about Medicare changes so you can be prepared for their impact.
Many retirees don't understand how their benefits change until they start to use their coverage.
10 prescription drugs with high costs may now be available at lower prices.
Medicare benefits provide health insurance coverage for most retirees, but the program can sometimes be complicated. In fact, while we are well into 2026 already, you may not have noticed that Medicare has changed in important ways this year if you haven't started using your benefits heavily yet.
Far too often, seniors don't find out about the changes in Medicare until they try to get care that is no longer covered, or until they find themselves facing bills that are different from what they expected.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
You don't want to be caught off guard, so be sure you're aware of these Medicare changes that have happened this year.
One of the first things that you should be aware of is that Medicare Advantage has introduced new coverage limits. Specifically, the Centers for Medicare and Medicaid Services imposed new restrictions on services that the Bipartisan Budget Act of 2018 had authorized for chronic illness sufferers.
Under the Bipartisan Budget Act, Advantage plans were allowed to provide broader coverage for treatments that improved life for people with chronic conditions. However, CMS is now prohibiting coverage for some of these services, including:
Advantage plan members must be aware of these restrictions on coverage.
Those with traditional Medicare have been impacted by changes as well.
Specifically, under the WISeR Model, new preauthorization requirements are in place for certain services covered by Medicare. These pre-authorization requirements may apply in six states: New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington.
The new requirements apply to services including:
If you need any of these treatments in the affected states, your doctor will likely need to get preapproval from Medicare before your insurance will pay for them.
While many of these changes aren't great news for retirees, there are some positive shifts for seniors.
Specifically, 10 prescription drugs with high costs may now be available at lower prices. That's because of the Medicare Drug Price Negotiation Program, which allows Medicare to negotiate for the first time to try to lower prices for costly treatments.
The drugs include:
If you use these drugs, the lower prices could help you keep more money in your retirement plans, like your 401(k) and IRA, instead of having to spend it on medication costs.
These are major changes every senior should be aware of, as shifts in Medicare can impact your retirement planning process in important ways as the cost of healthcare is a leading expense for most seniors.
If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income.
One easy trick could pay you as much as $23,760 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after. Join Stock Advisor to learn more about these strategies.
View the "Social Security secrets" »
The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The reduction of supplemental benefits in Medicare Advantage signals a structural shift from growth-at-all-costs to margin preservation for major health insurers."
The article frames these as 'Medicare changes,' but the real story is a tightening of the fiscal noose around Medicare Advantage (MA) profitability. By restricting supplemental benefits—which insurers used as a loss-leader to capture market share—CMS is forcing a pivot back toward core medical loss ratio (MLR) management. For payers like UnitedHealth (UNH) and Humana (HUM), this reduces the 'bells and whistles' marketing edge, potentially slowing enrollment growth. While the drug price negotiations provide a headline win for seniors, they represent a significant margin compression risk for Big Pharma, specifically impacting the long-term revenue tail of blockbuster drugs like Eliquis and Stelara.
These restrictions might actually stabilize MA plan solvency by curbing excessive 'give-back' benefits that were unsustainable, ultimately protecting the long-term viability of the private Medicare market.
"N/A"
[Unavailable]
"The article dramatizes three separate, limited policy changes as a unified Medicare overhaul when the real impact—at least in 2026—is narrow and mostly affects edge-case procedures and a small drug subset."
This article conflates three unrelated Medicare shifts and oversells their impact. The drug negotiation win (10 drugs, 2026 prices TBD) is real but narrow—these 10 represent ~2% of Medicare Part D spending. The WISeR preauth pilot affects only six states and targets low-volume, high-cost procedures (most won't touch typical retirees). The MA supplemental ban is genuine but applies only to new/renewal plans—existing members grandfathered in. The article's tone suggests systemic upheaval; the reality is incremental. Missing: actual negotiated price cuts (not yet public), WISeR's clinical outcomes data, and whether MA plans will simply rebrand restricted benefits as 'wellness' add-ons.
If CMS negotiation succeeds in forcing 20%+ price cuts on high-utilizers of these 10 drugs, and if WISeR expands to all states post-pilot, this could meaningfully compress pharma margins and reshape MA plan economics—the article's caution may underestimate structural change ahead.
"Net-net, headline drug-price relief is unlikely to translate into broad retiree savings due to plan design, access frictions, and geographic limitations."
Medicare changes are a mixed bag. The article leans into headline drug-price relief, but actual patient savings depend on plan design, formulary placement, and out-of-pocket structures, which can mute the impact. The WISeR preauthorization rollout in six states creates administrative friction and potential care delays, while the new MA benefit limits could reduce coverage retirees rely on for chronic conditions. Even with lower list prices for the 10 drugs, beneficiaries may not see big net savings if premiums rise or if access becomes more restricted. The net effect is uneven by state and by drug category, not a uniform uplift.
Counterpoint: the promised savings may never reach most beneficiaries because copays, deductibles, and formulary exclusions can swallow price cuts; and six-state preauthorizations may simply shift costs to providers or reduce use of needed therapies.
"The loss of supplemental benefit flexibility will trigger a valuation multiple compression for MA insurers by breaking the rebate-growth feedback loop."
Claude is right about the incremental nature of the drug negotiations, but both Claude and Gemini ignore the 'medical loss ratio' (MLR) trap. If MA plans can't use supplemental benefits to inflate their star ratings and capture federal rebates, the entire incentive structure for growth collapses. This isn't just about 'bells and whistles'; it’s about the underlying math of the MA business model. When the rebate-driven growth engine stalls, UNH and HUM face a multiple compression, not just margin contraction.
[Unavailable]
"MA margin compression is real, but the offsetting risk—network narrowing and premium hikes—may prove politically untenable and force CMS into a bind."
Gemini's MLR trap argument is sharp, but conflates two separate pressures. MA plans lose supplemental-benefit arbitrage *and* face drug price cuts simultaneously—but these hit different P&L lines. The real risk: if star ratings collapse without rebate-driven growth, plans pivot to aggressive network narrowing or premium increases to offset margin loss. That's the second-order effect nobody's modeled yet. Does CMS allow it, or does political pressure force them to cap premiums?
"Non-linear margin compression from the combo of MA changes and drug-price cuts could crater star-rating-driven growth and force aggressive network tightening or premium increases."
Claude, the incremental framing misses a non-linear risk: sweeping MA changes plus drug-price cuts could break the star-rating/rebate engine. If new plans lose supplemental-benefit arbitrage and margins compress, plans may not just rebrand benefits—they may tighten networks or lift premiums to preserve profitability. The risk is not gradual; it could reprice MA risk across the ecosystem, hitting UNH/HUM margins sooner than the market expects.
The panel agrees that the recent Medicare changes, particularly the tightening of Medicare Advantage (MA) supplemental benefits and drug price negotiations, pose significant risks to MA plans' profitability and growth. The changes could lead to a reduction in enrollment growth, margin compression for Big Pharma, and potential increases in premiums or network narrowing by MA plans to offset losses.
The collapse of the star-rating/rebate growth engine for MA plans, potentially leading to aggressive network narrowing or premium increases to offset margin loss.